Lexicon Pharmaceuticals Inc (LXRX)
1.60
-0.01
(-0.62%)
USD |
NASDAQ |
Apr 24, 16:00
1.595
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Revenue (TTM): 1.205M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.205M |
| September 30, 2023 | 0.531M |
| June 30, 2023 | 0.408M |
| March 31, 2023 | 0.126M |
| December 31, 2022 | 0.139M |
| September 30, 2022 | 0.125M |
| June 30, 2022 | 0.109M |
| March 31, 2022 | 0.308M |
| December 31, 2021 | 0.298M |
| September 30, 2021 | 0.483M |
| June 30, 2021 | 7.094M |
| March 31, 2021 | 16.02M |
| December 31, 2020 | 24.00M |
| September 30, 2020 | 32.52M |
| June 30, 2020 | 320.34M |
| March 31, 2020 | 320.86M |
| December 31, 2019 | 322.07M |
| September 30, 2019 | 330.42M |
| June 30, 2019 | 42.94M |
| March 31, 2019 | 47.05M |
| December 31, 2018 | 63.21M |
| September 30, 2018 | 80.54M |
| June 30, 2018 | 100.52M |
| March 31, 2018 | 98.77M |
| December 31, 2017 | 91.69M |
| Date | Value |
|---|---|
| September 30, 2017 | 76.24M |
| June 30, 2017 | 77.02M |
| March 31, 2017 | 85.06M |
| December 31, 2016 | 79.26M |
| September 30, 2016 | 187.58M |
| June 30, 2016 | 160.43M |
| March 31, 2016 | 140.72M |
| December 31, 2015 | 130.01M |
| September 30, 2015 | 24.22M |
| June 30, 2015 | 24.07M |
| March 31, 2015 | 24.37M |
| December 31, 2014 | 22.85M |
| September 30, 2014 | 2.782M |
| June 30, 2014 | 2.601M |
| March 31, 2014 | 2.139M |
| December 31, 2013 | 2.222M |
| September 30, 2013 | 1.03M |
| June 30, 2013 | 1.164M |
| March 31, 2013 | 1.149M |
| December 31, 2012 | 1.089M |
| September 30, 2012 | 1.214M |
| June 30, 2012 | 1.197M |
| March 31, 2012 | 1.553M |
| December 31, 2011 | 1.849M |
| September 30, 2011 | 2.759M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.109M
Minimum
Jun 2022
330.42M
Maximum
Sep 2019
74.74M
Average
1.205M
Median
Dec 2023
Revenue (TTM) Benchmarks
| Novavax Inc | 693.46M |
| AIM ImmunoTech Inc | 0.202M |
| Perspective Therapeutics Inc | 0.00 |
| Protalix BioTherapeutics Inc | 65.49M |
| Armata Pharmaceuticals Inc | -- |